Microinvasive squamous carcinoma of the cervix: treatment modalities by Mota, F
ACTA REVIEW
Microinvasive squamous carcinoma of the
cervix: treatment modalities
FERNANDO MOTA
Servic¸o De Ginecologia, Hospitais da Universidade de Coimbra, Coimbra, Portugal
Acta Obstet Gynecol Scand 2003; 82: 505–509. # Acta Obstet Gynecol Scand 82 2003
Patients with FIGO stage IA1 squamous cell carcinoma of the cervix can be treated
conservatively with simple hysterectomy or, if young and desiring to preserve their
fertility, with conization only, provided surgical margins are free of dysplasia or invasive
disease. When the surgical margins are involved a repeat conization should be performed.
Patients with FIGO stage IA2 or stage IA1 carcinoma with extensive lymph vascular space
invasion benefit from a modified radical hysterectomy with pelvic lymph node dissection.
If preservation of fertility is an issue, then conization with extraperitoneal or laparoscopic
pelvic lymphadenectomy can be performed. Alternatively, radical trachelectomy with
pelvic lymphadenectomy may be a safer procedure. Individualization of therapy based
on an exhaustive pathological evaluation of an adequate cone biopsy specimen is of
paramount importance for treatment planning and disease control.
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In 1994 FIGO (International Federation of Gyne-
cology and Obstetrics) defined microinvasive
squamous cell carcinoma of the uterine cervix
as a microscopic lesion that invaded below the
basement membrane to a maximum depth of
5 mm and with an horizontal spread not exceed-
ing 7 mm. The diagnosis should be based on
pathological examination of a cone biopsy
including the entire lesion to assess correctly
the depth and linear extent of invasion. These
microcarcinomas were further subdivided into
two categories/stages: IA1 defined as a tumor
that invaded to a depth of 3 mm or less, whereas
stage IA2 referred to tumors invading to a depth
greater than 3 mm and up to 5 mm. In both
stages, the horizontal spread should not exceed
7 mm, otherwise the tumor should be assigned to
stage IB. The depth of stromal invasion should
be measured from the base of the epithelium,
either squamous or glandular, from which it
originates to the deepest point of invasion. In
this classification lymph vascular space invasion
(LVSI) was not included as part of the defini-
tion, but FIGO recommended that it should be
recorded as it may affect treatment decisions in
the future.
The incidence of microinvasive cervical carcinoma
is steadily increasing, afflicts women predominantly
in their forties and fifties, and approximately
60–70% of patients have stage IA1 disease.
Concept of ‘early stromal invasion’
The purpose of defining microinvasive cervical
carcinoma is to identify a group of patients who
This paper substantiated participation in a symposium on
‘Pitfalls in the diagnosis and treatment of microinvasive
cervical cancer’ at the 11th World Congress of Cervical
Pathology and Colposcopy, Barcelona, June 2002.
Abbreviations:
CIN: cervical intraepithelial neoplasia; ESI: early stromal
invasion; FIGO: International Federation of Gynecology and
Obstetrics; HPV: human papillomavirus; LVSI: lymph vascular
space invasion
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are not at risk of lymph node metastases or tumor
recurrence and who therefore may be treated
conservatively. Some authorities (1) consider
that ‘early stromal invasion’ (ESI) is a unique
and distinct histological entity but it is not
included in FIGO classification. Early stromal
invasion is characterized by the presence of
microscopic epithelial neoplastic buds, which
emanate from the base of a carcinoma in situ
(CIN 3, high-grade squamous intraepithelial
lesion). This invasive focus consists of well-
differentiated cells with an abundant pink-staining
cytoplasm, and hyperchromatic nuclei, and are
surrounded by an inflammatory cell infiltrate
predominantly comprised of lymphocytes.
These early invasive lesions without measur-
able volume are not viewed as a separate entity
by FIGO classification and are lumped in with all
stage IA1 tumors. In fact, among a total of 429
women with invasion of less than 3 mm 80% had
ESI (2), which will dilute the group and improve
treatment results. Moreover, there are differences
in terms of vascular involvement, recurrences,
and survival between ESI and lesions invading
between 1 and 3 mm. This may result from the
fact that lymph vascular spaces are rare and
extremely small in the stroma adjacent to the
basement membrane. In an extensive review of
the literature, Ostor (3) reported that among 1409
women with ESI there were no lymph node
metastasis and only four cases were documented
with tumor recurrence (0.3%) (Table I). Hence,
the small foci of ESI apparently have no clinical
significance and therefore can be treated just like
in situ disease, provided the surgical margins are
clear. It should be noted, however, that extension
into the endocervical canal and glandular involve-
ment are greater than in CIN. Consequently, ESI
requires subsequent hysterectomy more often
than CIN.
Stage IA1 cervical carcinoma
In the above-mentioned literature review, Ostor
(3) reported that among 2274 women with squa-
mous lesions and stromal invasion of less than
1 mm, there were three cases of lymph node
metastases (0.1%) and eight cases in which
tumor recurrence developed (0.4%). In contrast,
among 1324 squamous lesions invading between
1 and 3 mm, there were five cases with lymph
node metastases (0.4%) and 23 cases with inva-
sive recurrence (1.7%) (Table I). Most of these
patients were treated conservatively.
Lymph vascular space invasion (LVSI) is
uncommon in stage IA1 disease, with Ostor (3)
reporting an incidence of 15%. It is known that
LVSI increases with increasing depth of invasion
(4) (Table II). As tumors invade more deeply into
the stroma, the incidence of LVSI increases from
4.4% with lesions infiltrating less than 1 mm to
approximately 20% in stage IA2 disease. It also
appears that patients most at risk of lymph node
metastases and recurrences are those with LVSI,
particularly with extensive involvement (4)
(Tables III and IV). These data show that as the
depth of stromal invasion increases, so does the
risk for nodal metastases and recurrences. Both
nodal disease and tumor recurrence are also intim-
ately correlated to LVSI. Others have corrob-
orated these observations (2,5,6). Therefore, it
Table I. Percentage of lymph node metastases, recurrences and death among
5681 patients with microinvasive carcinoma of the cervix
Stromal invasion Patients, n þnodes Recurrences Death
ESI 1409 0 0.3 0.07
<1 mm 2274 0.1 0.4 0.1
1–3 mm 1324 0.4 1.7 0.5
3.1–5 mm 674 2.1 3.7 1.9
ESI¼ early stromal invasion.
þnodes¼ lymph node metastases.
Table II. Incidence of lymph vascular space involvement by depth of stromal
invasion in microinvasive carcinoma of the cervix
Depth of invasion Patients, n þLVSI
<1 mm 548 24 (4.4%)
1–3 mm 596 98 (16.4%)
3.1–5 mm 350 69 (19.7%)
þLVSI¼ presence of lymph vascular space invasion.
Table III. Frequency (%) of lymph node metastases by depth of stromal




(n¼ 581)  3 mm 3.1–5 mm
Negative (n¼ 479) 0.8% 8.3%
Positive (n¼ 102) 8.2% 7.5%
LVSI¼ lymph vascular space invasion.
Table IV. Risk of recurrence (%) by depth of stromal invasion and lymph
vascular space involvement in microinvasive carcinoma of the cervix
LVSI
Depth of invasion
(n¼ 748)  3 mm 3.1–5 mm
Negative (n¼ 601) 0.6% 1.7%
Positive (n¼ 147) 3.1% 15.7%
LVSI¼ lymph vascular space invasion.
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seems prudent to treat patients exhibiting such
adverse parameters more aggressively.
Some authors consider confluent tumor
growth and poor cell differentiation as risk
factors for nodal metastases and recurrence.
However, the specificity of both variables is low,
and they may not represent independent prognos-
tic factors (7–9). This means that pattern of
invasion and tumor grade, on their own, should
not change treatment planning, but should be
recorded and alert to the clinical significance of
a particular lesion.
On the contrary, the status of the margins of
the conization specimen should be carefully
evaluated, as they are a significant predictor of
residual invasion (4,9–11). Roman et al. (11)
reported on 87 women with microinvasive carcin-
oma on conization specimens and followed by
either repeat conization or hysterectomy. Signifi-
cant predictors of residual invasion included
status of the internal margin (residual invasion
present in 22% of women with an involved mar-
gin vs. 3% with a negative margin; p< 0.03) and
the combined status of the internal margin and
postconization endocervical curettage (residual
invasion in 4% of patients if both negative, 13%
if one positive, and 33% if both positive;
p< 0.015). They concluded that ‘if either the
internal margin or the postconization endocer-
vical curettage contains dysplasia or carcinoma, the
risk of residual invasion is high and warrants
repeat conization before definitive treatment
planning’. However, it should be stressed that
the status of the postconization endocervical
curettage alone was not statistically significant
to predict residual invasion. Hence, many
clinicians do not perform routinely such a
procedure.
Considering the above-mentioned data, a con-
ization with clear surgical margins and no LVSI
is considered an adequate treatment for patients
with stage IA1 squamous cell carcinoma of the
cervix (Fig. 1). Nevertheless, patients must return
for regular follow-up examinations including
cytology, colposcopy and probably also onco-
genic HPV DNA testing, as this test may predict
persistence of residual disease or tumor recur-
rence. Conization is the treatment of choice for
young patients wishing to preserve their fertility.
Loop excision has gained wide acceptance and is
replacing cold-knife and laser conization. How-
ever, in large cervical lesions some authors (12)
prefer to perform a cold-knife conization rather
than a loop excision because the completeness of
the procedure is higher, and the rate of tissue
transection and misorientation is lower for the
cold-knife method.
If future childbearing is not required, simple
hysterectomy may be considered. Vaginal hyster-
ectomy is preferable because the cervix is excised
under direct visual control, whereas at abdominal
hysterectomy the lesion may be cut through. This
may explain the lower recurrence rates after
vaginal hysterectomy in comparison with the
abdominal approach. When colposcopic exam-
ination shows no evidence of extension of the
tumor onto the vaginal fornices, a vaginal cuff
does not need to be removed. Recurrences in the
vaginal vault usually result from the presence of
involvement of adjacent vaginal mucosa. This
could be prevented with a careful colposcopic
examination before surgery. If the vaginal for-
nices are involved, a partial vaginectomy will be
performed, preferably vaginally.
Whenever the cone margins or the postconization
endocervical curettage contain CIN or microinva-
sive carcinoma, or the postcone endocervical
cytology, on regular follow up, reveals dysplasia, a
repeat conization should be performed provided
there is still sufficient cervical tissue remaining,
which is often the case. A thorough pathologic
examination of the surgical specimen is important
to rule out microinvasive residual disease or even to
disclose a frank carcinoma. If residual disease is
Conization





• Cone margins with CIN or microinvasive disease
• Stage IA1 with extensive LVSI
• No LVSI
• Clear surgical margins
• Older patients
• Fertility not issue
• Stage IA2
• Post-cone cytology/biopsy with CIN
Conization
• Preservation of fertility or with pelviclymphadenectomy
Trachelectomy
• Childbearing not issue Type II modified radical hysterectomy
Fig. 1. Algorithm depicting the therapeutic strategy for
microinvasive squamous cell carcinoma of the uterine cervix.
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diagnosed, either a CIN lesion or microinvasive
tumor foci, a simple hysterectomy should be offered
to the patient. Women with stage IB tumors will
benefit from additional therapy according to estab-
lished protocols.
It is of paramount importance to identify the sub-
set of patients whose stage IA1 microinvasive
tumors are at high risk of recurrence and therefore
need to be treated more aggressively. Among the
variables that can predict such adverse behavior,
LVSI, especially when extensive, is the most import-
ant. Others (2) take also into account the poor
differentiation of the carcinoma, which is debatable.
In these circumstances, stage IA1 tumors with exten-
sive LVSI should benefit from a modified radical
hysterectomy with pelvic lymphadenectomy and
with parametrial preservation, as parametrial
invasion is extremely rare in microinvasive disease
(5,13). If childbearing is desired, it is possible to
perform a cone biopsy with extraperitoneal or
laparoscopic pelvic lymphadenectomy. Alterna-
tively, a safer option in the presence of extensive
LVSI may be to perform a radical trachelectomy
and pelvic lymph node dissection (Fig. 1).
Stage IA2 cervical carcinoma
In a review of the literature, Ostor (3) reported on
674 patients with microinvasive squamous cell
carcinomas with a depth of invasion between
3 and 5 mm, and a width of not more than 7 mm.
The incidence of lymph node metastases was
2.1%, invasive recurrence occurred in 25 cases
(3.7%), with 13 patients (1.9%) dying of their
disease (Table I). Many of these patients, 33 per
cent, were treated radically. Hence, these tumors
are less aggressive than frank carcinomas but
carry a greater risk of pelvic lymph node metas-
tases, recurrences and death from disease in com-
parison with their stage IA1 counterparts.
It is generally agreed that the recommended
treatment for stage IA2 squamous cell carcinoma
of the cervix is a type II modified radical hyster-
ectomy with pelvic lymph node dissection. However,
this procedure definitely represents overtreatment
for many patients, when more discriminative prog-
nostic parameters have yet to be identified to prevent
it. In young patients or when childbearing is desired,
treatment options are similar to those previously
described for stage IA1 lesions: conization with
extraperitoneal or laparoscopic pelvic lymph-
adenectomy. Radical trachelectomy with pelvic
lymphadenectomy (14) is a safer procedure when
there is LVSI, and may also be indicated when a
repeat conization is not possible in the presence of
surgical margins with CIN or microinvasive disease
(Fig. 1).
Finally, if nodal disease is not present no
further treatment is required. Conversely, if
lymph node metastases are identified pelvic irradi-
ation might be recommended. Microinvasive
squamous cell carcinoma in medically unfit
patients with contraindications to surgery can
be treated effectively with intracavitary
irradiation.
Concluding remarks
At least theoretically, patients with microinvasive
cervical carcinoma adequately studied and cor-
rectly treated should have survival rates ranging
from 98 to 100%. However, the last annual
report (FIGO’s Annual report, vol. 23, 1998)
documented a 5-year overall survival rate of
95.1% for stage IA1 disease (n¼ 518 patients)
and a similar rate of 94.9% for stage IA2
(n¼ 384). Efforts have to be made worldwide to
improve these results, which must be studied in
detail in order to corroborate the adequacy of the
1994 FIGO definition of microinvasive cervical
carcinoma or to change it.
It is of paramount importance to perform a
thorough pathological evaluation of an adequate
surgical cone to analyze tumor dimensions, mar-
gins, LVSI and eventually cell differentiation and
tumor confluence. It is also essential that there is
close cooperation between the gynecologist and
the pathologist, so that the best treatment modal-
ity is offered to the patient with microinvasive
cervical disease.
I would like to emphasize that treatment
should be individualized based on an integrated
assessment of multiple factors. Some of these are
related to the patient, such as age, childbearing
desire, compliance to regular follow up and can-
cerphobia. Other factors include pathological
parameters that should be considered, especially
tumor dimensions, status of the cone margins and
lymph vascular space invasion (Table V).
Furthermore, it is hoped that in the near future
Table V. Selection criteria for individualization of therapy in microinvasive









lymph vascular space invasion
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more discriminative molecular/genetic prognostic
markers that can assist in treatment planning
may be identified.
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